{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:52:56Z","timestamp":1776174776688,"version":"3.50.1"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Key Projects of New Drugs R&D","award":["2009ZX09103-117"],"award-info":[{"award-number":["2009ZX09103-117"]}]},{"DOI":"10.13039\/501100007129","name":"Shandong Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Development Foundation of Shandong Province","award":["2006GG2202063"],"award-info":[{"award-number":["2006GG2202063"]}]},{"name":"Key research and development project of Shandong Province","award":["2017CXGC1401"],"award-info":[{"award-number":["2017CXGC1401"]}]},{"name":"Major Project of Science and Technology of Shandong Province","award":["2015ZDJS04001"],"award-info":[{"award-number":["2015ZDJS04001"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ejmech.2018.01.097","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T12:55:26Z","timestamp":1517835326000},"page":"150-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives"],"prefix":"10.1016","volume":"147","author":[{"given":"Jinmi","family":"Zou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.01.097_bib1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nchem.2479","article-title":"Counting on natural products for drug design","volume":"8","author":"Rodrigues","year":"2016","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1631\/jzus.B1600094","article-title":"A\u00a0great honor and a huge challenge for China: You-you TU getting the Nobel Prize in physiology or medicine","volume":"17","author":"Yuan","year":"2016","journal-title":"J.\u00a0Zhejiang. Univ-sc. B."},{"key":"10.1016\/j.ejmech.2018.01.097_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jphp.12683","article-title":"Chinese herbal drugs for the treatment of diabetic retinopathy","volume":"69","author":"Behl","year":"2017","journal-title":"J.\u00a0Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jpba.2004.09.054","article-title":"Simultaneous quantification of 12 bioactive components of Ligusticum chuanxiong Hort. by high-performance liquid chromatography","volume":"37","author":"Yan","year":"2005","journal-title":"J.\u00a0Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2018.01.097_bib5","first-page":"427","article-title":"Preparation of cardiovascular disease-related genes microarray and its application in exploring ligustrazine-induced changes in endothelial gene expression","volume":"56","author":"Li","year":"2004","journal-title":"Pol. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.taap.2012.09.016","article-title":"Ligustrazine attenuates oxidative stress-induced activation of hepatic stellate cells by interrupting platelet-derived growth factor-\u03b2 receptor-mediated ERK and p38 pathways","volume":"265","author":"Zhang","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s13318-011-0032-2","article-title":"Pharmacokinetic study of a novel stroke therapeutic, 2-[[(1,1-dimethylethyl)oxidoimino]methyl]-3,5,6-trimethylpyrazine, by a simple HPLC-UV method in rats","volume":"36","author":"Li","year":"2011","journal-title":"Eur. J. Drug. Metab. Ph."},{"key":"10.1016\/j.ejmech.2018.01.097_bib8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bbr.2013.07.052","article-title":"Tetramethylpyrazine protects against scopolamine-induced memory impairments in rats by reversing the cAMP\/PKA\/CREB pathway","volume":"253","author":"Wu","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2018.01.097_bib9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.cellbi.2006.10.001","article-title":"Neuroprotective effects of tetramethylpyrazine on hydrogen peroxide-induced apoptosis in PC12 cells","volume":"31","author":"Cheng","year":"2007","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.ejmech.2018.01.097_bib10","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2174\/1871520615666150305112120","article-title":"Ligustrazine suppresses the growth of HRPC cells through the inhibition of cap- dependent translation via both the mTOR and the MEK\/ERK pathways","volume":"15","author":"Han","year":"2015","journal-title":"Anticancer. Agents. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0014-2999(90)94167-V","article-title":"Ligustrazine is a vasodilator of human pulmonary and bronchial arteries","volume":"191","author":"Liu","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib12","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1476-5381.1996.tb15778.x","article-title":"Ligustrazine-induced endothelium-dependent relaxation in pulmonary arteries via an NO-mediated and exogenous L-arginine-dependent mechanism","volume":"119","author":"Peng","year":"1996","journal-title":"Brit. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib13","first-page":"668","article-title":"Study on absolute bioavailability of liguzinediol in rats","volume":"31","author":"Shan","year":"2012","journal-title":"Chin. J. New. Drugs. Clin. Remed."},{"key":"10.1016\/j.ejmech.2018.01.097_bib14","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.bmcl.2015.12.072","article-title":"Synthesis and positive inotropic activity evaluation of liguzinediol metabolites","volume":"26","author":"Zhu","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.01.097_bib15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FJC.0000000000000467","article-title":"Liguzinediol enhances the inotropic effect of rat hearts via inhibition of protein phosphatase (PP1 and PP2A) activities","volume":"69","author":"Li","year":"2017","journal-title":"J.\u00a0Cardiovasc. Pharm."},{"key":"10.1016\/j.ejmech.2018.01.097_bib16","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/aps.2014.75","article-title":"Liguzinediol improved the heart function and inhibited myocardial cell apoptosis in rats with heart failure","volume":"35","author":"Li","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2018.01.097_bib17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.fitote.2013.04.006","article-title":"Systematic review of recent advances in pharmacokinetics of four classical Chinese medicines used for the treatment of cerebrovascular disease","volume":"88","author":"Zeng","year":"2013","journal-title":"Fitoterapia"},{"key":"10.1016\/j.ejmech.2018.01.097_bib18","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1358\/dof.2005.030.10.927377","article-title":"Recent advances in the structural modification of ligustrazine: cerebro- and cardiovascular activity of ligustrazine derivatives","volume":"30","author":"Cheng","year":"2005","journal-title":"Drug. Future"},{"key":"10.1016\/j.ejmech.2018.01.097_bib19","first-page":"258","article-title":"Effects of 2-hydroxymethyl-3,5,6-trimethyl-pyrazine on cardiovascular system","volume":"29","author":"Chen","year":"1998","journal-title":"Chin. J. Pharm."},{"key":"10.1016\/j.ejmech.2018.01.097_bib20","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3109\/13880209.2010.551776","article-title":"Ligustrazine improves atherosclerosis in rat via attenuation of oxidative stress","volume":"49","author":"Jiang","year":"2011","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib21","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s11164-013-1281-2","article-title":"An overview on structural modifications of ligustrazine and biological evaluation of its synthetic derivatives","volume":"41","author":"Xu","year":"2013","journal-title":"Res. Chem. Intermed."},{"key":"10.1016\/j.ejmech.2018.01.097_bib22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tips.2017.04.005","article-title":"Targeting free radicals in oxidative stress-related human diseases","volume":"38","author":"Poprac","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2018.01.097_bib23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jsbmb.2017.03.019","article-title":"GPER blockers as Nox downregulators: a new drug class to target chronic non-communicable diseases","volume":"176","author":"Meyer","year":"2017","journal-title":"J.\u00a0Steroid Biochem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biocel.2006.07.001","article-title":"Free radicals and antioxidants in normal physiological functions and human disease","volume":"39","author":"Valko","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib25","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.01.097_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5455\/oams.201113.rv.011","article-title":"Role of free radicals and antioxidants in gynecological cancers: current status and future prospects","volume":"3","author":"Valluru","year":"2014","journal-title":"Oxid. Antioxid. Med. Sci."},{"key":"10.1016\/j.ejmech.2018.01.097_bib27","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00204-010-0577-x","article-title":"Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples","volume":"84","author":"Kell","year":"2010","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib28","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCRESAHA.114.300559","article-title":"Cardiac mitochondria and ros generation","volume":"114","author":"Chen","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2018.01.097_bib29","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.3390\/md9101995","article-title":"Pardaxin, an antimicrobial peptide, triggers caspase-dependent and ROS-mediated apoptosis in HT-1080 cells","volume":"9","author":"Huang","year":"2011","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2018.01.097_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041340","volume":"7","author":"Esser","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.01.097_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.2171","article-title":"The redox-sensitive cation channel TRPM2 modulates phagocyte ROS production and inflammation","volume":"13","author":"Di","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib32","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/CIR.0000000000000350","article-title":"Heart disease and stroke Statistics-2016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2018.01.097_bib33","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/CIRCRESAHA.113.300219","article-title":"Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions","volume":"113","author":"Sanganalmath","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2018.01.097_bib34","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.ehj.2004.03.011","article-title":"Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences","volume":"25","author":"Viles-Gonzalez","year":"2004","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2018.01.097_bib35","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2174\/156652410791065264","article-title":"Anti-atherothrombogenic properties of PEDF","volume":"10","author":"Yamagishi","year":"2010","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.ejmech.2018.01.097_bib36","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/fcp.12133","article-title":"Pharmacokinetics and metabolism of Chf197, a ligustrazine derivative, in rats","volume":"29","author":"Li","year":"2015","journal-title":"Fund. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib37","first-page":"133","article-title":"Comparison of pharmacological effects of tetramethylpyrazine and deuterated tetramethylpyrazines","volume":"2","author":"Jiang","year":"1996","journal-title":"Chin. Pharmacol. Bull."},{"key":"10.1016\/j.ejmech.2018.01.097_bib38","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1016\/j.bmc.2007.03.033","article-title":"Design, synthesis, and biological activities of novel Ligustrazine derivatives","volume":"15","author":"Cheng","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib39","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1016\/j.bmc.2009.03.012","article-title":"Ligustrazine derivatives. Part 3: design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents","volume":"17","author":"Cheng","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib40","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1016\/j.ejmech.2011.09.030","article-title":"Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents","volume":"46","author":"Chen","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib41","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1039\/c4md00022f","article-title":"Design, synthesis and biological evaluation of novel trimethylpyrazine-2-carbonyloxy-cinnamic acids as potent cardiovascular agents","volume":"5","author":"Chen","year":"2014","journal-title":"Medchemcommun"},{"key":"10.1016\/j.ejmech.2018.01.097_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/ndt\/gfg340","article-title":"Alcohol and red wine: impact on cardiovascular risk","volume":"19","author":"Bohm","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejmech.2018.01.097_bib43","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1747-0285.2012.01332.x","article-title":"Ligustrazine derivatives. Part 4: design, synthesis, and biological evaluation of novel ligustrazine-based stilbene derivatives as potential cardiovascular agents","volume":"79","author":"Deng","year":"2012","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2018.01.097_bib44","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/jphp.12168","article-title":"DLJ14, a novel chemo-sensitization agent, enhances therapeutic effects of adriamycin against MCF-7\/A cells both in\u00a0vitro and in\u00a0vivo","volume":"66","author":"Zhang","year":"2014","journal-title":"J.\u00a0Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5582\/ddt.8.33","article-title":"Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR\/PI3K\/Akt survival pathway and induction of apoptosis","volume":"8","author":"Chen","year":"2014","journal-title":"Drug. Discov. Ther."},{"key":"10.1016\/j.ejmech.2018.01.097_bib46","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.tiv.2011.03.002","article-title":"Ligustrazine derivate DLJ14 reduces multidrug resistance of K562\/A02 cells by modulating GSTpi activity","volume":"25","author":"Song","year":"2011","journal-title":"Toxicol. In. Vitro"},{"key":"10.1016\/j.ejmech.2018.01.097_bib47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1021\/jm00121a041","article-title":"Synthesis of acylguanidine analogues: inhibitors of ADP-induced platelet aggregation","volume":"32","author":"Thomas","year":"1989","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib48","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2174\/157340612802084243","article-title":"Ligustrazine derivatives. Part 6: design, synthesis and evaluation of novel ligustrazinyl acylguanidine derivatives as potential cardiovascular agents","volume":"8","author":"Li","year":"2012","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/157340641130900042","article-title":"Ligustrazine derivatives. Part 8: design, synthesis, and preliminary biological evaluation of novel Ligustrazinyl amides as cardiovascular agents","volume":"10","author":"Li","year":"2014","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib50","series-title":"Tanshinol Derivatives as Calcium Ion Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of Cardiovascular and Cerebrovascular Diseases","author":"Wang","year":"2016"},{"key":"10.1016\/j.ejmech.2018.01.097_bib51","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/351895","article-title":"Tanshinol attenuates the deleterious effects of oxidative stress on osteoblastic differentiation via Wnt\/FoxO3a signaling","volume":"2013","author":"Yang","year":"2013","journal-title":"Oxid. Med. Cell. Longev"},{"key":"10.1016\/j.ejmech.2018.01.097_bib52","series-title":"Preparation of Pyrazine Derivatives Useful for Treating Disease Such as Cardiovascular and Cerebrovascular Diseases","author":"Wang","year":"2015"},{"key":"10.1016\/j.ejmech.2018.01.097_bib53","series-title":"Preparation of Benzyl Alcohol Ether Compounds for Preventing And\/or Treating Cardiovascular and Cerebrovascular Diseases","author":"Song","year":"2015"},{"key":"10.1016\/j.ejmech.2018.01.097_bib54","series-title":"Preparation of Picotamide Analogs Useful in the Treatment or Prevention of Thromboembolic Disorders","author":"Li","year":"2014"},{"key":"10.1016\/j.ejmech.2018.01.097_bib55","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1211\/0022357044247","article-title":"Structure-activity relationship studies on chalcone derivatives: potent inhibition of platelet aggregation","volume":"56","author":"Ko","year":"2004","journal-title":"J.\u00a0Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib56","series-title":"Ligustrazine Chalcone Aryloxy Alkyl Acid Compounds as Platelet Aggregation Inhibitors and Their Preparation,pharmaceutical Compositions and Use in the Treatment of Hyperlipidemia and Atherosclerosis","author":"Li","year":"2016"},{"key":"10.1016\/j.ejmech.2018.01.097_bib57","series-title":"Benzyl Alcohols and Nitrate Derivatives as Platelet Aggregation Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of Thrombosis","author":"Song","year":"2015"},{"key":"10.1016\/j.ejmech.2018.01.097_bib58","series-title":"A\u00a0Process for Preparing Thienopyridine Derivatives as Platelet Aggregation Inhibitors","author":"Zhong","year":"2013"},{"key":"10.1016\/j.ejmech.2018.01.097_bib59","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.01.097_bib60","series-title":"Dabigatran Derivatives as Oral Thrombin Inhibitors and Their Preparation, Pharmaceutical Compositions and Use in the Treatment of Thrombosis","author":"Xu","year":"2012"},{"key":"10.1016\/j.ejmech.2018.01.097_bib61","first-page":"1","article-title":"Cancer statistics","volume":"59","author":"Jemal","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2018.01.097_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-7258(03)00042-1","article-title":"Natural products for cancer prevention: a global perspective","volume":"99","author":"Reddy","year":"2003","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2018.01.097_bib63","doi-asserted-by":"crossref","first-page":"223","DOI":"10.15430\/JCP.2015.20.4.223","article-title":"Natural products for chemoprevention of breast cancer","volume":"20","author":"Eun-Yi","year":"2015","journal-title":"J.\u00a0Cancer. Prev."},{"key":"10.1016\/j.ejmech.2018.01.097_bib64","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2174\/1871520615666150305112120","article-title":"Ligustrazine suppresses the growth of HRPC cells through the inhibition of cap- dependent translation via both the mTOR and the MEK\/ERK pathways","volume":"15","author":"Han","year":"2015","journal-title":"Anticancer. Agents. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib65","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.canlet.2014.01.016","article-title":"Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence","volume":"346","author":"Shanmugam","year":"2014","journal-title":"Cancer. Lett."},{"key":"10.1016\/j.ejmech.2018.01.097_bib66","first-page":"211","article-title":"Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells","volume":"23","author":"Wang","year":"2010","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2018.01.097_bib67","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.3390\/molecules20022728","article-title":"The multifaceted role of curcumin in cancer prevention and treatment","volume":"20","author":"Shanmugam","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2018.01.097_bib68","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.3390\/molecules17054972","article-title":"Synthesis and biological evaluation of new ligustrazine derivatives as anti-tumor agents","volume":"17","author":"Wang","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2018.01.097_bib69","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.01.097_bib70","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.colsurfb.2015.04.002","article-title":"Optimizing the design and in\u00a0vitro, evaluation of bioreactive glucose oxidase-microspheres for enhanced cytotoxicity against multidrug resistant breast cancer cells","volume":"130","author":"Cheng","year":"2015","journal-title":"Colloids. Surf. B. Biointerfaces"},{"key":"10.1016\/j.ejmech.2018.01.097_bib71","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1021\/acs.jmedchem.5b01203","article-title":"Discovery of new monocarbonyl ligustrazine\u2013curcumin hybrids for intervention of drug-sensitive and drug-resistant lung cancer","volume":"59","author":"Yong","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib72","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejmech.2013.11.024","article-title":"A\u00a0\"natural\" approach: synthesis and cytoxicity of monodesmosidic glycyrrhetinic acid glycosides","volume":"72","author":"Schwarz","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib73","doi-asserted-by":"crossref","first-page":"21035","DOI":"10.3390\/ijms160921035","article-title":"A\u00a0series of new ligustrazine-triterpenes derivatives as anti-tumor agents: design, synthesis, and biological evaluation","volume":"16","author":"Xu","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2018.01.097_bib74","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejmech.2017.02.036","article-title":"Combination of amino acid\/dipeptide with ligustrazine-betulinic acid as antitumor agents","volume":"130","author":"Xu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib75","first-page":"911","article-title":"Identification of metabolites of antitumor lead compound T-OA in rat urine by HPLC-HRMS","volume":"39","author":"Xu","year":"2014","journal-title":"China J. Chin. Mater. Med."},{"key":"10.1016\/j.ejmech.2018.01.097_bib76","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/03639045.2013.858739","article-title":"In-vitro and in-vivo comparison of T-OA microemulsions and solid dispersions based on EPDC","volume":"41","author":"Hou","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejmech.2018.01.097_bib77","doi-asserted-by":"crossref","first-page":"18215","DOI":"10.3390\/molecules191118215","article-title":"Amino acid derivatives of ligustrazine-oleanolic acid as new cytotoxic agents","volume":"19","author":"Chu","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2018.01.097_bib78","first-page":"46330","article-title":"Molecular docking studies and biological evaluation of chalcone based pyrazolines as tyrosinase inhibitors and potential anticancer agents","volume":"25","author":"Bukhari","year":"2015","journal-title":"Rsc. Adv."},{"key":"10.1016\/j.ejmech.2018.01.097_bib79","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1021\/acs.jmedchem.6b00276","article-title":"Synthesis of \u03b1,\u03b2-unsaturated carbonyl-based compounds, oxime and oxime ether analogs as potential anticancer agents for overcoming cancer multidrug resistance by modulation of efflux pumps in tumor cells","volume":"59","author":"Qin","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejmech.2017.04.025","article-title":"Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance","volume":"135","author":"Zha","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib81","series-title":"Preparation of the Ligustrazine Derivatives and Their Application as the Anticancer Agents","author":"Li","year":"2017"},{"key":"10.1016\/j.ejmech.2018.01.097_bib82","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejmech.2015.03.035","article-title":"Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors","volume":"95","author":"Zhang","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib83","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/j.1471-4159.2007.04866.x","article-title":"Neuroprotection and stroke: time for a compromise","volume":"103","author":"Young","year":"2007","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib84","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nature04960","article-title":"Stem cells for the treatment of neurological disorders","volume":"441","author":"Lindvall","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.01.097_bib85","first-page":"442","article-title":"The protective effect of ligustrazine on optic nerve axons in rabbit eyes with continuous elevated IOP","volume":"36","author":"Li","year":"2000","journal-title":"Chin. J. Ophthalmol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib86","first-page":"1002","article-title":"Effect of salviae miltiorrhizae and ligustrazine hydrochloride injection on axonal regeneration and nerve growth factor expression in a rat model of sciatic nerve injury","volume":"4","author":"Ma","year":"2009","journal-title":"Neural. Regen. Res."},{"key":"10.1016\/j.ejmech.2018.01.097_bib87","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1474-9726.2006.00189.x","article-title":"Nitrones as therapeutics in age-related diseases","volume":"5","author":"Floyd","year":"2006","journal-title":"Aging Cell"},{"key":"10.1016\/j.ejmech.2018.01.097_bib88","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.freeradbiomed.2008.08.017","article-title":"Nitrones as therapeutics","volume":"45","author":"Floyd","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2018.01.097_bib89","doi-asserted-by":"crossref","first-page":"8868","DOI":"10.1016\/j.bmc.2008.08.075","article-title":"Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke","volume":"16","author":"Sun","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib90","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neulet.2010.03.016","article-title":"Protocatechuic acid inhibits neurotoxicity induced by MPTP in\u00a0vivo","volume":"474","author":"Zhang","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2018.01.097_bib91","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1006\/phrs.2000.0717","article-title":"Effects of salicylic acid in glutamate- and kainic acid-induced neurotoxicity in cerebellar granular cell culture of rats","volume":"42","author":"Gepdiremen","year":"2000","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2018.01.097_bib92","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.2174\/092986712800672102","article-title":"Protocatechuic acid and human disease prevention: biological activities and molecular mechanisms","volume":"19","author":"Masella","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib93","first-page":"2679","article-title":"Synthesis and protective effect of ligustrazine intermediates against CoCl2-induced neurotoxicity in differentiated PC12 cell","volume":"39","author":"Li","year":"2014","journal-title":"China J. Chin. Mater. Med."},{"key":"10.1016\/j.ejmech.2018.01.097_bib94","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1086\/BBLv224n1p18","article-title":"Ferulic acid: a natural antioxidant against oxidative stress induced by oligomeric a-beta on sea urchin embryo","volume":"224","author":"Picone","year":"2013","journal-title":"Biol. Bull."},{"key":"10.1016\/j.ejmech.2018.01.097_bib95","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.neulet.2012.12.051","article-title":"Protective effects of caffeic acid and caffeic acid phenethyl ester against acrolein-induced neurotoxicity in HT22 mouse hippocampal cells","volume":"535","author":"Huang","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2018.01.097_bib96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13065-015-0084-5","article-title":"Ligustrazinyl amides: a novel class of ligustrazine-phenolic acid derivatives with neuroprotective effects","volume":"9","author":"Li","year":"2015","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.ejmech.2018.01.097_bib97","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3109\/13880209.2014.935866","article-title":"Cognitive effects of vanillic acid against streptozotocin-induced neurodegeneration in mice","volume":"53","author":"Singh","year":"2015","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib98","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13065-017-0250-z","article-title":"Synthesis and protective effect of new ligustrazine-vanillic acid derivatives against CoCl2-induced neurotoxicity in differentiated PC12 cells","volume":"11","author":"Xu","year":"2017","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.ejmech.2018.01.097_bib99","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1039\/C7MD00003K","article-title":"Design, synthesis and evaluation of new ligustrazine derivatives as potential plasma-stable neuroprotective agents","volume":"8","author":"Zhang","year":"2017","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2018.01.097_bib100","series-title":"Preparation of Chlorooxime Compounds for Treatment of Neurodegenerative Disease","author":"Wang","year":"2014"},{"key":"10.1016\/j.ejmech.2018.01.097_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","article-title":"Bad bugs, No drugs: No ESKAPE! An update from the infectious diseases society of America","volume":"48","author":"Boucher","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2018.01.097_bib102","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1039\/C7OB00053G","article-title":"Amphipathic guanidine-embedded glyoxamide-based peptidomimetics as novel antibacterial agents and biofilm disruptors","volume":"15","author":"Nizalapur","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib103","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1128\/AAC.43.8.2059","article-title":"In\u00a0vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci","volume":"43","author":"Noskin","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.01.097_bib104","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/anie.200200528","article-title":"Oxazolidinone structure\u2014activity relationships leading to linezolid","volume":"42","author":"Barbachyn","year":"2003","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2018.01.097_bib105","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1128\/AAC.01193-07","article-title":"R\u00a0chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance","volume":"52","author":"Skripkin","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.01.097_bib106","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1016\/j.bmcl.2009.09.054","article-title":"Synthesis and biological activity of novel oxazolidinones","volume":"19","author":"Das","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.01.097_bib107","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/cbdd.12537","article-title":"Novel oxazolidinone antibacterial analogues with a substituted ligustrazine C-ring unit","volume":"86","author":"Chen","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2018.01.097_bib108","first-page":"1","article-title":"Synthesis of novel tetrazole containing hybrid ciprofloxacin and pipemidic acid analogues and preliminary biological evaluation of their antibacterial and antiproliferative activity","volume":"14","author":"Dileep","year":"2017","journal-title":"Mol. Div."},{"key":"10.1016\/j.ejmech.2018.01.097_bib109","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ejmech.2014.07.066","article-title":"Structure and evaluation of antibacterial and antitubercular properties of new basic and heterocyclic 3-formylrifamycin SV derivatives obtained via 'click chemistry' approach","volume":"84","author":"Pyta","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.01.097_bib110","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature07201","article-title":"Origin and physiological roles of inflammation","volume":"454","author":"Medzhitov","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.01.097_bib111","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.expneurol.2013.04.010","article-title":"Tetramethylpyrazine reduces cellular inflammatory response following permanent focal cerebral ischemia in rats","volume":"247","author":"Kao","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib112","first-page":"233","article-title":"Anti-inflammatory and profibrinolytic effect of tetramethylpyrazine in acute coronary syndromes","volume":"2","author":"Wu","year":"2005","journal-title":"J.\u00a0Geriater. Cardiol."},{"key":"10.1016\/j.ejmech.2018.01.097_bib113","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12906-017-1739-7","article-title":"Anti-inflammatory effect of combined tetramethylpyrazine, resveratrol and curcumin in\u00a0vivo","volume":"17","author":"Chen","year":"2017","journal-title":"Bmc. Complement. Altern. Med."},{"key":"10.1016\/j.ejmech.2018.01.097_bib114","series-title":"Preparation of Rhein Ether Derivatives for Preventing and Treating T Cell Proliferation Associated or Proinflammatory Cytokines Mediated Diseases","author":"Li","year":"2011"},{"key":"10.1016\/j.ejmech.2018.01.097_bib115","series-title":"Preparation of Rhein derivatives for preventing or treating cardiovascular diseases, T-cell proliferationrelated or pro-inflammatory cytokine-mediated diseases","author":"Li","year":"2011"},{"key":"10.1016\/j.ejmech.2018.01.097_bib116","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1016\/j.bbagen.2013.02.008","article-title":"Natural products: a continuing source of novel drug leads","volume":"1830","author":"Cragg","year":"2013","journal-title":"Biochim. Biophys. Acta"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418301193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418301193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T04:55:08Z","timestamp":1570683308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418301193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":116,"alternative-id":["S0223523418301193"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.01.097","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.01.097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}